行情

NYMX

NYMX

Nymox
NASDAQ

实时行情|Nasdaq Last Sale

3.060
-0.045
-1.45%
休市 16:00 01/17 EST
开盘
3.050
昨收
3.105
最高
3.120
最低
3.050
成交量
8.53万
成交额
--
52周最高
3.280
52周最低
1.320
市值
2.14亿
市盈率(TTM)
-15.6362
分时
5日
1月
3月
1年
5年

NYMX 新闻

  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57
  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57
  • Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology
  • GlobeNewswire.01/06 16:00
  • OCUL, ACOR, INCY and DPW among midday movers
  • Seeking Alpha - Article.01/03 17:41

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

NYMX 简况

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
展开

Webull提供Nymox Pharmaceutical Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。